MUVON's Phase II study to continue
16-01-2025 – The International Data Safety Monitoring Board has recommended the continuation of MUVON Therapeutic's SUISSE MPC2 study, an indication that the startup is on schedule for the release of the final data and completion of the phase II study scheduled for Q3 2025.
In this phase of the SUISSE MPC2 study (NCT05534269), measurable data from 10 female patients were included, with a 6-month follow up window, following the injection of the tissue-engineered product into the urethal muscle.
The study aims to assess the safety and efficacy of MUVON’s Muscle Precursor Cell (MPC)-based therapy to treat Stress Urinary Incontinence (SUI), a condition where there is involuntary leakage of urine during activities that put pressure on the bladder, for example, laughing, coughing, or lifting heavy weights. Such a condition occurs due to weakened muscles and tissues that support the bladder, preventing the bladder from holding urine during physical stress.
